Get started
Work

Figure 1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Year: 2024
Type: other
Abstract: PFS in patients who received prior ET+CDK4/6i ≥12 months in the metastatic setting. Kaplan–Meier estimates of PFS in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months in the metastatic setting (n = 159).
DOI: 10.1158/1078-0432.27142531
Authors: Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4403043810
Cites:
Cited by:
Related to: 10